Marius Roman

Marius Roman

Auto-generated profile, based on publicly available information

Marius Roman

University of Leicester Department of Cardiovascular Sciences

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015
Verified
Journal Article
Open access
ECEdward Joseph Caruana
Edward Joseph Caruana
MRMarius Roman
Marius Roman
JHJules Hernández-Sánchez
Jules Hernández-Sánchez
PSPiergiorgio Solli
Piergiorgio Solli

1 January 2021 in British Journal of Anaesthesia
Verified
Journal Article
Open access
MRMarius A. Roman
Marius A. Roman
RARiccardo G. Abbasciano
Riccardo G. Abbasciano
SPSuraj Pathak
Suraj Pathak
SOShwe Oo
Shwe Oo
SYSyabira Yusoff
Syabira Yusoff
GMGavin J. Murphy
Gavin J. Murphy
Patient blood management (PBM) interventions aim to improve clinical outcomes by reducing bleeding and transfusion. We assessed whether existing evidence supports the routine use of combinations of these interventions during and after major surgery. Five systematic reviews and a National Institute of Health and Care Excellence health economic review of trials of common PBM interventions enrolling participants of any age undergoing surgery were updated. The last search was on June 1, 2019. Studies in trauma, burns, gastrointestinal haemorrhage, gynaecology, dentistry, or critical care were excluded. The co-primary outcomes were: risk of receiving red cell transfusion and 30-day or hospital all-cause mortality. Treatment effects were estimated using random-effects models and risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity assessments used I2. Network meta-analyses used a frequentist approach. The protocol was registered prospectively (PROSPERO CRD42018085730). Searches identified 393 eligible randomised controlled trials enrolling 54 917 participants. PBM interventions resulted in a reduction in exposure to red cell transfusion (RR=0.60; 95% CI 0.57, 0.63; I2=77%), but had no statistically significant treatment effect on 30-day or hospital mortality (RR=0.93; 95% CI 0.81, 1.07; I2=0%). Treatment effects were consistent across multiple secondary outcomes, sub-groups and sensitivity analyses that considered clinical setting, type of intervention, and trial quality. Network meta-analysis did not demonstrate additive benefits from the use of multiple interventions. No trial demonstrated that PBM was cost-effective. In randomised trials, PBM interventions do not have important clinical benefits beyond reducing bleeding and transfusion in people undergoing major surgery.

1 April 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MRMarius Roman
Marius Roman
Fausto BiancariFausto Biancari
Fausto Biancari
AAAamer B. Ahmed
Aamer B. Ahmed
SASeema Agarwal
Seema Agarwal
LHLeon Hadjinikolaou
Leon Hadjinikolaou
GMGiovanni Mariscalco
Giovanni Mariscalco

1 September 2017 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
AAAnders S.I. Andreasson
Anders S.I. Andreasson
LBLee A. Borthwick
Lee A. Borthwick
CGColin Gillespie
Colin Gillespie
KJKasim Jiwa
Kasim Jiwa
JSJonathan Scott
Jonathan Scott
AFAndrew Fisher
Andrew Fisher
Extended criteria donor lungs deemed unsuitable for immediate transplantation can be reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can be successfully reconditioned and will function well post-operatively has not been established. This study assessed the predictive value of markers of inflammation and tissue injury in donor lungs undergoing EVLP as part of the DEVELOP-UK study. Longitudinal samples of perfusate, bronchoalveolar lavage, and tissue from 42 human donor lungs undergoing clinical EVLP assessments were analyzed for markers of inflammation and tissue injury. Levels were compared according to EVLP success and post-transplant outcomes. Neutrophil adhesion to human pulmonary microvascular endothelial cells (HPMECs) conditioned with perfusates from EVLP assessments was investigated on a microfluidic platform. The most effective markers to differentiate between in-hospital survival and non-survival post-transplant were perfusate interleukin (IL)-1β (area under the curve = 1.00, p = 0.002) and tumor necrosis factor-α (area under the curve = 0.95, p = 0.006) after 30 minutes of EVLP. IL-1β levels in perfusate correlated with upregulation of intracellular adhesion molecule-1 in donor lung vasculature (R2 = 0.68, p < 0.001) and to a lesser degree upregulation of intracellular adhesion molecule-1 (R2 = 0.30, p = 0.001) and E-selectin (R2 = 0.29, p = 0.001) in conditioned HPMECs and neutrophil adhesion to conditioned HPMECs (R2 = 0.33, p < 0.001). Neutralization of IL-1β in perfusate effectively inhibited neutrophil adhesion to conditioned HPMECs (91% reduction, p = 0.002). Donor lungs develop a detectable and discriminatory pro-inflammatory signature in perfusate during EVLP. Blocking the IL-1β pathway during EVLP may reduce endothelial activation and subsequent neutrophil adhesion on reperfusion; this requires further investigation in vivo.

1 February 2019 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MRM. Roman
M. Roman
AMA. Monaghan
A. Monaghan
GSG. F. Serraino
G. F. Serraino
DMD. Miller
D. Miller
SPS. Pathak
S. Pathak
GMG. J. Murphy
G. J. Murphy

1 July 2015 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MRMarius Roman
Marius Roman
OGOlivera Gjorgjimajkoska
Olivera Gjorgjimajkoska
DNDesley Neil
Desley Neil
SNSukumaran Nair
Sukumaran Nair
SCSimon Colah
Simon Colah
STSteven Tsui
Steven Tsui